2.Deep vein thrombosis and pulmonary embolism: The drug lenalidomide
/dexamethasone group, deep vein thrombosis (DVT) is reported as the rate of serious adverse drug reactions (7.4%) or grade three-quarters adverse drug reactions (8.2%) were higher than in the placebo/dexamethasone group (3.1% and 3.4% respectively).There was a similar rate of withdrawal between the two groups due to deep vein thrombosis.
According to the mid-term data of MM-021 in patients with myeloma in China, 1 case of deep venous thrombosis (DVT) was observed in 199 patients. All subjects were treated with thrombus prevention in accordance with the protocol. Decisions should be made on whether preventive measures should be taken after assessing the potential risk factors for individual patients.
In the drug lenalidomide/dexamethasone group, pulmonary embolism is reported as serious adverse drug reaction, including grade three-quarters (3.7%). This adverse reaction rate is higher than placebo/dexamethasone group (0.9%). There was a similar rate of withdrawal between the two groups due to pulmonary embolism.